Boraginaceae cynoglossum plant and new application of extractive thereof

Abstract

The invention belongs to the field of medicine, and relates to a boraginaceae cynoglossum plant and new application of extractive thereof, in particular to the Boraginaceae cynoglossum plant and the application of the extractive of the Boraginaceae cynoglossum plant in preparation of medicine treating fundus maculopathy, wherein fundus maculopathy includes central exudative chorioretinopathy, central serous chorioretinopathy, senile macular degeneration, diabetic fundus macular degeneration, hypertensive macular degeneration and the like. Preparations prepared from the boraginaceae cynoglossum plant and the extractive of the boraginaceae cynoglossum plant serving as active ingredients have remarkable curative effects on fundus maculopathy and are safe and free of side effects. The boraginaceae cynoglossum plant belongs to a natural medicinal material and is wide in source, so that a novel choice is provided for treating the diseases clinically.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a new application of a plant of the genus Glaucoma of the family Boraginaceae and an extract thereof. Background technique [0002] The fundus is composed of the retina, fundus blood vessels, optic nerve head, optic nerve fibers, macula on the retina, and choroid behind the retina. The lesions in these parts are collectively called fundus diseases. The "macula" is a normal physiological area on the retina of the fundus, located in the center of the retina, where a large number of visual function cells are concentrated, and can recognize most optical signals such as shape, size, color, depth, distance, etc., and is an important part that determines visual function. [0003] Fundus macular degeneration is a common disease that affects the macula in middle-aged and elderly people. Blindness causes great distress to the life and physical and mental health of middle-aged and elder...

AI Technical Summary

Problems solved by technology

[0008] Laser therapy and photodynamic therapy can only seal the existing new blood vessels, but cannot prevent the formation of new new blood vessels, so it is only a symptomatic treatment

These treatments are not only expensive, but also often require multiple operations depending on the condition, which is a high financial burden for patients

Anti-vascular endothelial growth factor (VEGF) biological agent therapy has many shortcomings or defects: 1) It can only control the development of the disease, but cannot change the pathological damage that has been caused

2) Unstable efficacy, unsatisfactory clinical expectations, high recurrence rate, and certain adverse reactions and risks

For example, the curative effect of ranibizumab gradually fades in the later stage of the course of treatment, and there is a potential risk of blindness in the late stage of long-term use of anti-vascular endothelial growth factor (VEGF) preparations, etc.

3) The cost is expensive, ranging from thousands of yuan to tens of thousands of yuan per injection. In China, three injections are generally required. According to the treatment standard in the United States, one injection per month for the first three months, and at least seven or eight injections per year for the next three years

[0012] There is no relevant report about the application of the medicinal composition containing the plant of the genus Glacis of the family Boraginaceae alone or containing the plant of the genus Glaucoma in the treatment of retinal macular degeneration